Bone Marrow Transplantation最新文献

筛选
英文 中文
Oral malignant and potentially malignant lesions after allogenic hematopoietic cell transplantation: a 10-year follow-up study. 异基因造血细胞移植后的口腔恶性和潜在恶性病变:一项为期 10 年的随访研究。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-19 DOI: 10.1038/s41409-024-02443-8
H Mawardi, S Elad, Y Zadik, M E Correa, O Felemban, N S Treister
{"title":"Oral malignant and potentially malignant lesions after allogenic hematopoietic cell transplantation: a 10-year follow-up study.","authors":"H Mawardi, S Elad, Y Zadik, M E Correa, O Felemban, N S Treister","doi":"10.1038/s41409-024-02443-8","DOIUrl":"https://doi.org/10.1038/s41409-024-02443-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of bacterial blood stream infections in patients with acute GVHD. 急性 GVHD 患者细菌性血流感染的发生率。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-18 DOI: 10.1038/s41409-024-02426-9
Whitney Wallis, Alison M Gulbis, Tao Wang, Catherine J Lee, Akshay Sharma, Kirsten M Williams, Taiga Nishihori, Tim Prestidge, Lohith Gowda, Michael Byrne, Maxwell M Krem, Margaret L MacMillan, Carrie L Kitko, Joseph Pidala, Stephen R Spellman, Stephanie J Lee, Amin M Alousi
{"title":"Incidence of bacterial blood stream infections in patients with acute GVHD.","authors":"Whitney Wallis, Alison M Gulbis, Tao Wang, Catherine J Lee, Akshay Sharma, Kirsten M Williams, Taiga Nishihori, Tim Prestidge, Lohith Gowda, Michael Byrne, Maxwell M Krem, Margaret L MacMillan, Carrie L Kitko, Joseph Pidala, Stephen R Spellman, Stephanie J Lee, Amin M Alousi","doi":"10.1038/s41409-024-02426-9","DOIUrl":"https://doi.org/10.1038/s41409-024-02426-9","url":null,"abstract":"<p><p>Bacterial bloodstream infections (BSI) can be a substantial contributor to complications of GVHD treatment. The aim of this study was to determine the risk for BSI from neutrophil engraftment through day 100 post transplant in patients with acute GVHD (AGVHD) based on organ involvement and severity. Patients (n = 4064) who underwent an allogeneic hematopoietic stem cell transplant (HCT) reported to the CIBMTR registry were analyzed. Grade II-IV AGVHD occurred in 1607 (39.5%) patients and was associated with a greater day-100 incidence of post engraftment BSI than with grade 0/I (24.9 vs. 15.3%). Patients with grade III/IV AGVHD had the highest BSI risk (HR 2.45; 95% CI 1.99-3.0; p < 0.0001). Lower GI involvement increased BSI risk (HR 1.54; 95% CI 1.17-2.02; p = 0.0019). BSI post-engraftment through day 100 was associated with worse survival (HR 1.64, 95% CI 1.43-1.87; p < 0.001) and higher non-relapse mortality (NRM), (HR 2.22; 95% CI 1.91-2.59; p < 0.001). Those with stage III/IV GI involvement are at highest risk for BSI. Future studies evaluating novel methods for preventing BSI in these high risk populations are needed to reduce mortality associated with AGVHD.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. 作者更正:多发性骨髓瘤患者进行自体干细胞移植时使用和不使用普利沙佛的动员策略。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-18 DOI: 10.1038/s41409-024-02442-9
Zachary M Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel, Joseph Bubalo, Gary Milkovich, Erin Moshier, Weijia Fu, Ajai Chari, Joshua Richter
{"title":"Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.","authors":"Zachary M Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel, Joseph Bubalo, Gary Milkovich, Erin Moshier, Weijia Fu, Ajai Chari, Joshua Richter","doi":"10.1038/s41409-024-02442-9","DOIUrl":"https://doi.org/10.1038/s41409-024-02442-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia. 急性髓性白血病异基因移植前可测量的残留FLT3酪氨酸激酶结构域突变。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-18 DOI: 10.1038/s41409-024-02444-7
Pranay S Hegde, Georgia Andrew, Gege Gui, Niveditha Ravindra, Devdeep Mukherjee, Zoë C Wong, Jeffery J Auletta, Firas El Chaer, Adam Corner, Steven M Devine, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan
{"title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia.","authors":"Pranay S Hegde, Georgia Andrew, Gege Gui, Niveditha Ravindra, Devdeep Mukherjee, Zoë C Wong, Jeffery J Auletta, Firas El Chaer, Adam Corner, Steven M Devine, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan","doi":"10.1038/s41409-024-02444-7","DOIUrl":"https://doi.org/10.1038/s41409-024-02444-7","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party. 更正:ECP与Ruxolitinib治疗类固醇难治性慢性GVHD--EBMT移植并发症工作组的一项回顾性研究。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-18 DOI: 10.1038/s41409-024-02435-8
Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, H Christian Reinhardt, Ksenia Afanasyeva, Daniele Avenoso, Tobias A W Holderried, Brian Thomas Kornblit, Eleni Gavriilaki, Carmen Martinez, Patrizia Chiusolo, Maria Caterina Mico, Elisabeth Daguenet, Stina Wichert, Hakan Ozdogu, Agnieszka Piekarska, Francesca Kinsella, Grzegorz W Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric
{"title":"Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.","authors":"Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, H Christian Reinhardt, Ksenia Afanasyeva, Daniele Avenoso, Tobias A W Holderried, Brian Thomas Kornblit, Eleni Gavriilaki, Carmen Martinez, Patrizia Chiusolo, Maria Caterina Mico, Elisabeth Daguenet, Stina Wichert, Hakan Ozdogu, Agnieszka Piekarska, Francesca Kinsella, Grzegorz W Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric","doi":"10.1038/s41409-024-02435-8","DOIUrl":"https://doi.org/10.1038/s41409-024-02435-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autologous hematopoietic stem cell transplantation in a patient with multi-refractory stiff person syndrome. 自体造血干细胞移植治疗一名多次难治性僵人综合征患者。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-17 DOI: 10.1038/s41409-024-02440-x
Tamim Alsuliman, Dimitri Psimaras, Nicolas Stocker, Simona Sestili, Anne Banet, Zoé Van de Wyngaert, Agnès Bonnin, Manuela Badoglio, Mathieu Puyade, Dominique Farge, Mohamad Mohty, Zora Marjanovic
{"title":"Autologous hematopoietic stem cell transplantation in a patient with multi-refractory stiff person syndrome.","authors":"Tamim Alsuliman, Dimitri Psimaras, Nicolas Stocker, Simona Sestili, Anne Banet, Zoé Van de Wyngaert, Agnès Bonnin, Manuela Badoglio, Mathieu Puyade, Dominique Farge, Mohamad Mohty, Zora Marjanovic","doi":"10.1038/s41409-024-02440-x","DOIUrl":"https://doi.org/10.1038/s41409-024-02440-x","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematopoietic stem cell transplantation in children with mucopolysaccharidosis IVA: single center experience. 粘多糖病IVA患儿的造血干细胞移植:单中心经验。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-14 DOI: 10.1038/s41409-024-02439-4
Koray Yalcin, Vedat Uygun, Burcu Ozturk Hismi, Suna Celen, Seda Ozturkmen, Suleimen Zhumatayev, Hayriye Daloglu, Gülsün Karasu, Akif Yesilipek
{"title":"Hematopoietic stem cell transplantation in children with mucopolysaccharidosis IVA: single center experience.","authors":"Koray Yalcin, Vedat Uygun, Burcu Ozturk Hismi, Suna Celen, Seda Ozturkmen, Suleimen Zhumatayev, Hayriye Daloglu, Gülsün Karasu, Akif Yesilipek","doi":"10.1038/s41409-024-02439-4","DOIUrl":"https://doi.org/10.1038/s41409-024-02439-4","url":null,"abstract":"<p><p>Mucopolysaccharidosis IVA (MPS IVA; Morquio syndrome) is a lysosomal storage disorder and features systemic skeletal dysplasia that is caused by defective Nacetylgalactosamine-6-sulfate sulfatase (GALNS). Although there are convincing data for hematopoietic stem cell transplantation (HSCT) in certain types of MPS, the studies are limited for MPS IVA and more data is still pending to show the efficacy/safety of HSCT. This study included 3 girls and 7 boys, with a median age of 75,5 months (35-186 months), who underwent allogeneic HSCT for severe MPS IVA between February 12, 2021, and March 10, 2023. Enzyme levels, height growth, the most involved organs (ear, eye, and heart), and the activities of daily living (ADL) scoring system were monitored to assess the benefit of HSCT. In a median follow-up of 20 months (9-34 months), there is no severe transplant-related adverse event was observed. In all cases, normal enzyme levels were reached after HSCT. During the short follow-up period, our cases showed an increase in stature and improvement in daily activity functions. Here we present the data of our HSCT experience in MPS IVA with promising results regarding both safety and efficacy. Although there are signs of amelioration with HSCT, we need more data and long-term follow-up to comment properly on the benefits of HSCT in MPS IVA.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion. 血液系统恶性肿瘤的同种异体造血干细胞移植:使用抗T淋巴细胞免疫球蛋白代替抗胸腺细胞球蛋白进行体内T细胞耗竭的新型调理方案。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-14 DOI: 10.1038/s41409-024-02433-w
Xiao-Bing Huang, Xi Yang, Cheng-Long Li, Rong Zhang, Wen Wang, Jia-Wen Huang, Xue-Mei Ye, Yu Wang, Yan Mao, Wen-Qi Pu, Yang Zhou
{"title":"Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.","authors":"Xiao-Bing Huang, Xi Yang, Cheng-Long Li, Rong Zhang, Wen Wang, Jia-Wen Huang, Xue-Mei Ye, Yu Wang, Yan Mao, Wen-Qi Pu, Yang Zhou","doi":"10.1038/s41409-024-02433-w","DOIUrl":"https://doi.org/10.1038/s41409-024-02433-w","url":null,"abstract":"<p><p>We evaluated the safety and efficacy of a novel protocol for haploidentical stem cell transplantation (haplo-SCT) in 312 patients with hematologic malignancies. The protocol evolved from the Beijing platform replacing ATG with ATLG; adding Fludarabine and removing cytarabine and Simustine. GVHD prophylaxis combined Basiliximab and low-dose cyclophosphamide post-transplant; overall, the conditioning duration was shortened. Median times to neutrophil and platelet recovery were both 11 days. Graft rejection occurred in 0.96% of patients. Cumulative incidences of grades II-IV and III-IV acute GVHD by day 200 were 35.3% and 8.9%, respectively. Probabilities of total and extensive chronic GVHD at 2 years were 40.7% and 14.7%. CMV viremia was observed in 35.6% of patients, with a 1.9% 100-day CMV pneumonia incidence and no CMV-related mortality. Cumulative incidences of non-relapse mortality at 100 days, 1 year, and 2 years were 2.9, 4.4, and 6.6%. The 4-year OS, RFS, and GRFS rates were 78.9, 70.7, and 47.3%. Older recipient age was associated with higher NRM, while positive pre-transplant MRD predicted worse OS, RFS, and higher relapse incidence. Our novel protocol for haplo-SCT is associated with low infection rates and acceptable risks of graft failure, severe GVHD, and mortality, representing a safe and effective haploidentical transplantation strategy.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT. 特定骨髓纤维化人群移植资格评估过程中的 "灰色地带 "和挑战:代表 EBMT 慢性恶性肿瘤工作组的观点。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-14 DOI: 10.1038/s41409-024-02437-6
Nicola Polverelli, Juan Carlos Hernández-Boluda, Nico Gagelmann, Carmelo Gurnari, Michele Malagola, Fernando Barroso Duarte, Vaneuza A M Funke, Caterina Zerbi, Donal P McLornan
{"title":"Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT.","authors":"Nicola Polverelli, Juan Carlos Hernández-Boluda, Nico Gagelmann, Carmelo Gurnari, Michele Malagola, Fernando Barroso Duarte, Vaneuza A M Funke, Caterina Zerbi, Donal P McLornan","doi":"10.1038/s41409-024-02437-6","DOIUrl":"https://doi.org/10.1038/s41409-024-02437-6","url":null,"abstract":"<p><p>Significant efforts have been made to effectively select myelofibrosis (MF) patients who can benefit from allogeneic hematopoietic cell transplantation (allo-HCT), the only current cure for MF. The recent EBMT/ELN 2024 recommendations offer valuable guidance for hematologists and transplant physicians. However, several grey areas remain in day-to-day clinical practice regarding the feasibility and optimal preparation for transplantation in patients with this disease. Effective spleen size reduction, often achieved with JAK inhibitors, appears crucial for transplant success. For resistant cases, switching JAK inhibitors, splenectomy, or spleen irradiation may be considered, taking into account patient profiles, treatment availability and center preferences. Managing splanchnic vein thromboses, portal, and pulmonary hypertension is critical as these conditions may affect transplant outcomes. Cytopenias, particularly transfusion-dependent anemia and thrombocytopenia, complicate treatment and impact on outcomes, though new drugs show promise. Comorbidities play a significant role and tools like the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) and frailty assessments are useful for evaluating transplant risks while allowing the implementation of corrective measures. Especially in low- and medium-income countries where access to novel therapies may be challenging, allo-HCT still represents an attractive therapeutic option for MF. Future directions include integrating new therapeutics into the transplant algorithm and leveraging artificial intelligence for more informed risk assessment, highlighting the need for tailored approaches to improve allo-HCT outcomes in such a setting.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients. 更正:预测异体造血细胞移植受者呼吸道病毒性疾病进展的新因素。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-11 DOI: 10.1038/s41409-024-02418-9
Chikara Ogimi, Hu Xie, Alpana Waghmare, Keith R Jerome, Wendy M Leisenring, Masumi Ueda Oshima, Paul A Carpenter, Janet A Englund, Michael Boeckh
{"title":"Correction: Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients.","authors":"Chikara Ogimi, Hu Xie, Alpana Waghmare, Keith R Jerome, Wendy M Leisenring, Masumi Ueda Oshima, Paul A Carpenter, Janet A Englund, Michael Boeckh","doi":"10.1038/s41409-024-02418-9","DOIUrl":"https://doi.org/10.1038/s41409-024-02418-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信